Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.
URL: http://www.news-medical.net/news/20130201/Galectin-submits-GR-MD-02-IND-application-with-FDA-for-treatment-of-liver-fibrosis.aspx
No comments:
Post a Comment